517 results on '"Scher, Jose U."'
Search Results
2. Prevention of Psoriatic Arthritis: The Need for Prospective Studies
3. New Frontiers in Psoriatic Disease Research, Part I: Genetics, Environmental Triggers, Immunology, Pathophysiology, and Precision Medicine
4. Sociodemographic and clinical characteristics associated with multiple biologic failure in psoriasis: A 2015-2022 prospective cohort analysis of the CorEvitas psoriasis registry
5. Methotrexate impacts conserved pathways in diverse human gut bacteria leading to decreased host immune activation
6. Auto-deconvolution and molecular networking of gas chromatography-mass spectrometry data.
7. Responsiveness and Minimum Clinically Important Difference in Patient‐Reported Outcome Measures Among Patients With Psoriatic Arthritis: A Prospective Cohort Study
8. Interleukin‐17 Inhibition in Spondyloarthritis Is Associated With Subclinical Gut Microbiome Perturbations and a Distinctive Interleukin‐25–Driven Intestinal Inflammation
9. Efficacy and safety of guselkumab in patients with active psoriatic arthritis who had inadequate efficacy and/or intolerance to one prior tumor necrosis factor inhibitor: study protocol for SOLSTICE, a phase 3B, multicenter, randomized, double-blind, placebo-controlled study
10. Psoriatic arthritis from a mechanistic perspective
11. Racial and ethnic determinants of psoriatic arthritis phenotypes and disease activity
12. Psoriatic Arthritis
13. Evaluation of SARS-CoV-2 IgG antibody reactivity in patients with systemic lupus erythematosus: analysis of a multi-racial and multi-ethnic cohort
14. National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2—Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments
15. CCL20 in psoriasis: A potential biomarker of disease severity, inflammation, and impaired vascular health
16. Microbial-derived antigens and metabolites in spondyloarthritis
17. Consensus terminology for preclinical phases of psoriatic arthritis for use in research studies: results from a Delphi consensus study
18. National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1
19. Key opinion leaders — a critical perspective
20. Mitigation of Osteoclast‐Mediated Arthritic Bone Remodeling By Short Chain Fatty Acids.
21. Microbiome and Microbiota in Rheumatic Disease
22. Not your average joint: Towards precision medicine in psoriatic arthritis
23. Use of the Bath Ankylosing Spondylitis Disease Activity Index in Patients With Psoriatic Arthritis With and Without Axial Disease
24. SHORT CHAIN FATTY ACIDS MITIGATE OSTEOCLAST‐MEDIATED ARTHRITIC BONE REMODELLING
25. Psoriatic arthritis
26. KLK6 expression in skin induces PAR1-mediated psoriasiform dermatitis and inflammatory joint disease
27. Pharmacomicrobiomics in inflammatory arthritis: gut microbiome as modulator of therapeutic response
28. Use of the Bath Ankylosing Spondylitis Disease Activity Index in Patients With Psoriatic Arthritis With and Without Axial Disease.
29. Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Network Consortium (PPACMAN) 2021 Annual Meeting Proceedings
30. Activated Platelets Induce Endothelial Cell Inflammatory Response in Psoriasis Via COX-1
31. Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition
32. Spatial transcriptomics stratifies psoriatic disease severity by emergent cellular ecosystems
33. Periodontal Infections and Rheumatoid Arthritis
34. Clinical Validation of Digitally Acquired Clinical Data and Machine Learning Models for Remote Measurement of Psoriasis and Psoriatic Arthritis: A Proof-of-Concept Study
35. Aiming for Cure and Preventive Initiatives in Psoriatic Disease: Building Synergy at NPF, GRAPPA, and PPACMAN
36. Healthcare resource utilization and costs associated with inflammatory bowel disease among patients with chronic inflammatory diseases: a retrospective cohort study
37. Strategies to Improve Outcomes in Psoriatic Arthritis
38. Paradoxical Effects of Depression on Psoriatic Arthritis Outcomes in a Combined Psoriasis-Psoriatic Arthritis Center.
39. Psoriatic Arthritis
40. Prevention of psoriatic arthritis: the next frontier
41. Human microbiome, infections, and rheumatic disease
42. A Joint Effort: Improving the Identification of Spondyloarthritis in Patients With Inflammatory Bowel Disease
43. Potential risk factors for reactive arthritis and persistence of symptoms at 2 years: a case-control study with longitudinal follow-up
44. Supplemental Material - Paradoxical Effects of Depression on Psoriatic Arthritis Outcomes in a Combined Psoriasis-Psoriatic Arthritis Center
45. Inflammasome Signaling and Impaired Vascular Health in Psoriasis
46. Responsiveness and Minimum Clinically Important Difference in Patient‐ReportedOutcome Measures Among Patients With Psoriatic Arthritis: A Prospective Cohort Study
47. Alterations in the cutaneous microbiome of patients with psoriasis and psoriatic arthritis reveal similarities between non-lesional and lesional skin
48. Efficacy of guselkumab, a selective IL-23 inhibitor, in Preventing Arthritis in a Multicentre Psoriasis At-Risk cohort (PAMPA): protocol of a randomised, double-blind, placebo controlled multicentre trial
49. Selective oral ROCK2 inhibitor down-regulates IL-21 and IL-17 secretion in human T cells via STAT3-dependent mechanism
50. 22 - The microbiome in rheumatic diseases
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.